Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Gross Margin % : -2,439.77% (As of Dec. 2023)

Great Novel Therapeutics Biotech & Medicals Gross Margin % Chart

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross Margin %	Get a 7-Day Free Trial					40.61	85.93	-	-	-2,439.77

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's Gross Margin %

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Gross Margin % falls into.

Great Novel Therapeutics Biotech & Medicals Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Great Novel Therapeutics Biotech & Medicals's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Great Novel Therapeutics Biotech & Medicals's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Great Novel Therapeutics Biotech & Medicals had a gross margin of -2,439.77% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Great Novel Therapeutics Biotech & Medicals Gross Margin % Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description